Pharmaceutical

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

The US FDA has accepted for review BeiGene’s sNDA for Brukinsa plus obinutuzumab to treat follicular lymphoma.

Jul 13, 2023 - 20:00
FDA accepts BeiGene’s sNDA for follicular lymphoma therapy
The US FDA has accepted for review BeiGene’s sNDA for Brukinsa plus obinutuzumab to treat follicular lymphoma.
Read the original article

Tags:

Previous Article

Tenpoint raises funds to develop cell therapies for vision loss

Next Article

ICR to enter AI-powered cancer drug discovery partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

JURA Bio and Syena partner to develop TCR-based therapies

JURA Bio and Syena partner to develop TCR-based therapies

Sep 23, 2023

STAT+: When it comes to policing pharma, the FTC says it’s on ‘an incredible winning streak’

STAT+: When it comes to policing pharma, the FTC says i...

Jan 24, 2024

MiNA and BioMarin partner to speed development of RNAa therapies

MiNA and BioMarin partner to speed development of RNAa ...

Apr 26, 2023